TRANSCENTA-B (06628) has reached a strategic cooperation and non-exclusive technology license agreement with Tai Kang Life Sciences.

TRANSCENTA-B (06628) announced that it has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing company (TWSE: 6589). According to the agreement, the company will grant EirGenix a non-exclusive license to its highly integrated continuous flow bioprocessing (HiCB) platform, covering high-yield continuous perfusion upstream processes and integrated continuous downstream purification technologies, as well as providing comprehensive process documents, core process technology, experience, and regulatory support services. The company will receive a substantial upfront payment and milestone payments, and may also receive future royalties for the commercialization of the licensed technology, reflecting the shared expectation of creating long-term value through this collaboration. The HiCB platform aims to achieve higher process efficiency, optimize process control, and product consistency, significantly reducing production costs compared to traditional fed-batch production processes, ultimately enabling more global patients to access high-quality, affordable biologics. Through this collaboration, EirGenix will use the company's HiCB platform to support its biologics development projects and manufacturing operations. EirGenix plans to use the HiCB platform to serve CDMO customers seeking highly integrated continuous flow production solutions. "We are delighted to share the HiCB platform - the company's leading achievements in the field of highly integrated continuous flow bioprocessing - with like-minded partners to drive the transformation of biologics production," said Dr. Joyce Chien, Chairman and Chief Executive Officer of the company. "By enabling partners to apply the HiCB platform, we can collectively advance the affordability and global accessibility of innovative biologics. The benefits generated from this and future collaborations will be reinvested in strengthening the technology platform and advancing the R&D pipeline, dedicated to developing the next generation of best-in-class innovative therapies."